Conatus Pharmaceuticals, Inc. (CNAT)

Conatus-Pharma-logoConatus Pharmaceuticals, Inc. is a biotechnology company that develops and commercializes novel medicines for the treatment of liver disease. Conatus develops emracasan, the company’s lead compound for treating patients suffering from chronic liver disease, as well as acute exacerbations of chronic liver disease. An orally active pan-caspase protease inhibitor, emracasan is designed for reduction of the activity of ten human caspases, the enzymes mediating inflammation and death of cells, or apoptosis.

The company believes that emracasan has the capability to interrupt the progress of liver disease, and can provide options for treatment in various areas of liver disease based on the preclinical and clinical trial results suggesting that emracasan has the potential to slow the progression of liver disease, regardless of its original cause. Emracasan has been studied in ten clinical trials with more than 500 subjects.

In the Phase 2b of clinical trial in liver disease patients, emracasan has demonstrated a consistent, rapid, significant, and sustained reduction of elevated levels of alanine aminotransferase (ALT) and cleaved Cytokeratin 18 (cCK18), the two key biomarkers of cell death and inflammation that are implicated in the progression and severity of liver disease.

Conatus Pharmaceuticals, Inc. has designed a clinical program demonstrating emracasan’s therapeutic benefits across the spectrum of fibrotic liver disease. The company’s strategy focuses on targeting of indications for emracasan in small patient populations, including the small population of patients with chronic liver failure (CLF), and acute-on-chronic liver failure (ACLF).

Conatus Pharmaceuticals, Inc. is traded in the OTC markets under the stock symbol CNAT. The company is committed to serving the best interests of their shareholders. They provide key shareholder information and financial reports to help put the company’s financial performance into perspective.


Yahoo! Finance: CNAT News

Latest Financial News for CNAT

Intercept (ICPT) Gains 7.5% YTD on Progress in NASH Space

Intercept (ICPT) stock gains as it becomes the forerunner in the NASH drug race.

NASH Scorecard Year to Date: The Winners and the Losers

NASH sees a highly rewarding market with candidates of blockbuster potential. Let us take a look at the hits and misses in this space so far this year.

Conatus Pharmaceuticals Appoints Kathy Scott as Independent Board Member

SAN DIEGO, Nov. 18, 2019 -- Conatus Pharmaceuticals Inc. (NASDAQ: CNAT) today announced the appointment of Kathleen D. Scott to the Conatus Board of Directors as an additional.

Conatus Pharmaceuticals (CNAT) Reports Q3 Loss, Misses Revenue Estimates

Conatus (CNAT) delivered earnings and revenue surprises of 16.67% and -48.06%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

Conatus Pharmaceuticals Reports Third Quarter 2019 Financial Results

SAN DIEGO, Nov. 05, 2019 -- Conatus Pharmaceuticals Inc. (Nasdaq:CNAT) today announced financial results for the quarter and nine months ended September 30, 2019. Recent.